Roth Capital Comments on biote’s Q4 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Equities researchers at Roth Capital cut their Q4 2024 earnings per share estimates for shares of biote in a report issued on Wednesday, November 13th. Roth Capital analyst G. Kelly now expects that the company will earn $0.13 per share for the quarter, down from their prior estimate of $0.19. The consensus estimate for biote’s current full-year earnings is $0.53 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.67 EPS.

biote Stock Down 18.0 %

BTMD stock opened at $5.39 on Thursday. The stock has a 50-day simple moving average of $5.53 and a two-hundred day simple moving average of $6.28. biote has a twelve month low of $3.65 and a twelve month high of $8.44. The firm has a market capitalization of $292.24 million, a PE ratio of 20.73 and a beta of 0.94.

Hedge Funds Weigh In On biote

Several hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in biote in the 2nd quarter valued at $42,000. The Manufacturers Life Insurance Company bought a new stake in biote during the second quarter valued at $84,000. MetLife Investment Management LLC grew its position in biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after buying an additional 9,343 shares in the last quarter. Jane Street Group LLC increased its stake in biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after acquiring an additional 3,342 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of biote in the 3rd quarter valued at about $104,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.